APO Research
Talk to an analyst

APO RESEARCH · REPORT

PMO (Phosphorodiamidate Morpholino Oligomers) Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Growth and Trends Forecast to 2032

28 December 202587 pages

Choose your research edition.

Industry ResearchPMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

According to APO Research, the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market include Avidity Biosciences, Dyne, Nippon Shinyaku, NS Pharma, Inc. and Sarepta Therapeutics, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The PMO (Phosphorodiamidate Morpholino Oligomers) Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PMO (Phosphorodiamidate Morpholino Oligomers) Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Company

Avidity Biosciences

Dyne

Nippon Shinyaku

NS Pharma, Inc.

Sarepta Therapeutics, Inc

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type

DMD exon 45 Based

DMD exon 51 Based

DMD exon 53 Based

Other

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application

Hospital

Clinic

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2021-2026) Table 4. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2027-2032) Table 6. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Type (2021-2026) Table 9. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Application (2021-2026) Table 24. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends Table 37. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers Table 38. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges Table 39. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints Table 40. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Company (2021-2026) Table 42. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Company Headquarters & Area Served Table 44. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company, Product Type & Application Table 45. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Avidity Biosciences Company Information Table 49. Avidity Biosciences Business Overview Table 50. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 52. Avidity Biosciences Recent Development Table 53. Dyne Company Information Table 54. Dyne Business Overview Table 55. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 57. Dyne Recent Development Table 58. Nippon Shinyaku Company Information Table 59. Nippon Shinyaku Business Overview Table 60. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 62. Nippon Shinyaku Recent Development Table 63. NS Pharma, Inc. Company Information Table 64. NS Pharma, Inc. Business Overview Table 65. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 67. NS Pharma, Inc. Recent Development Table 68. Sarepta Therapeutics, Inc Company Information Table 69. Sarepta Therapeutics, Inc Business Overview Table 70. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 72. Sarepta Therapeutics, Inc Recent Development Table 73. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 74. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US$ Million) Table 75. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2026) Table 76. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 77. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share Forecast by Country (2027-2032) Table 78. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 79. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US$ Million) Table 80. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2026) Table 81. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 82. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share Forecast by Country (2027-2032) Table 83. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 84. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US$ Million) Table 85. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2026) Table 86. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 87. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share Forecast by Country (2027-2032) Table 88. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US$ Million) Table 90. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2026) Table 91. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share Forecast by Country (2027-2032) Table 93. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US$ Million) Table 95. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2026) Table 96. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share Forecast by Country (2027-2032) Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Image Figure 3. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region: 2025 VS 2032 Figure 6. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2021-2032) Figure 7. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. DMD exon 45 Based Image Figure 13. Global DMD exon 45 Based Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. DMD exon 51 Based Image Figure 15. Global DMD exon 51 Based Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. DMD exon 53 Based Image Figure 17. Global DMD exon 53 Based Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Other Image Figure 19. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type 2025 VS 2032 Figure 22. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Type (2021-2032) Figure 23. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Type (2021-2032) Figure 25. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Type (2021-2032) Figure 27. Hospital Image Figure 28. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Clinic Image Figure 30. Global Clinic Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application 2025 VS 2032 Figure 33. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Application (2021-2032) Figure 34. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Application (2021-2032) Figure 36. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 43. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 46. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 49. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 52. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • DMD exon 45 Based
  • DMD exon 51 Based
  • DMD exon 53 Based
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Avidity Biosciences
  • Dyne
  • Nippon Shinyaku
  • NS Pharma, Inc.
  • Sarepta Therapeutics, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  8. 1.5.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2021-2032)
2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 DMD exon 45 Based
  3. 2.1.2 DMD exon 51 Based
  4. 2.1.3 DMD exon 53 Based
  5. 2.1.4 Other
  6. 2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
  7. 2.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Regions
  11. 2.3.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2021-2026)
3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Clinic
  4. 3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
  5. 3.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Regions
  9. 3.3.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends
  2. 4.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers
  3. 4.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges
  4. 4.4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (2021-2026)
  2. 5.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Company Headquarters & Area Served
  4. 5.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company, Product Type & Application
  5. 5.5 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Avidity Biosciences
  2. 6.1.1 Avidity Biosciences Company Information
  3. 6.1.2 Avidity Biosciences Business Overview
  4. 6.1.3 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  6. 6.1.5 Avidity Biosciences Recent Developments
  7. 6.2 Dyne
  8. 6.2.1 Dyne Company Information
  9. 6.2.2 Dyne Business Overview
  10. 6.2.3 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  12. 6.2.5 Dyne Recent Developments
  13. 6.3 Nippon Shinyaku
  14. 6.3.1 Nippon Shinyaku Company Information
  15. 6.3.2 Nippon Shinyaku Business Overview
  16. 6.3.3 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  18. 6.3.5 Nippon Shinyaku Recent Developments
  19. 6.4 NS Pharma, Inc.
  20. 6.4.1 NS Pharma, Inc. Company Information
  21. 6.4.2 NS Pharma, Inc. Business Overview
  22. 6.4.3 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  24. 6.4.5 NS Pharma, Inc. Recent Developments
  25. 6.5 Sarepta Therapeutics, Inc
  26. 6.5.1 Sarepta Therapeutics, Inc Company Information
  27. 6.5.2 Sarepta Therapeutics, Inc Business Overview
  28. 6.5.3 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  30. 6.5.5 Sarepta Therapeutics, Inc Recent Developments
7 North America
  1. 7.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  3. 7.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  3. 8.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  3. 10.3 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst